Alto Neuroscience, Inc.

NYSE ANRO

Alto Neuroscience, Inc. Price to Earnings Ratio (P/E) on February 05, 2025: -1.97

Alto Neuroscience, Inc. Price to Earnings Ratio (P/E) is -1.97 on February 05, 2025, a 87.79% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Alto Neuroscience, Inc. 52-week high Price to Earnings Ratio (P/E) is -1.71 on December 18, 2024, which is 13.33% above the current Price to Earnings Ratio (P/E).
  • Alto Neuroscience, Inc. 52-week low Price to Earnings Ratio (P/E) is -14.36 on February 06, 2024, which is -628.48% below the current Price to Earnings Ratio (P/E).
  • Alto Neuroscience, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -6.37.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
SV Wall Street
NYSE: ANRO

Alto Neuroscience, Inc.

CEO Dr. Amit Etkin M.D., Ph.D.
IPO Date Feb. 2, 2024
Location United States
Headquarters 369 South San Antonio Road
Employees 78
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Mental Health Robotics
Description

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.

StockViz Staff

February 7, 2025

Any question? Send us an email